PRODUCT LITERATURE

Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections

---

The global threat of the spread of carbapenem resistance in Enterobacteriaceae has led to the search for new antibacterials.
Intravenous meropenem/vaborbactam (Vabomere™) is the frst carbapenem/β-lactamase inhibitor combination approved in the
USA for use in patients with complicated urinary tract infections (cUTIs), including pyelonephritis. Vaborbactam is a potent
inhibitor of class A serine carbapenemases, which, when combined with the antibacterial meropenem, restores the activity of
meropenem against β-lactamase producing Enterobacteriaceae, particularly Klebsiella pneumoniae carbapenemase (KPC)-
producing Enterobacteriaceae. Meropenem/vaborbactam demonstrated excellent in vitro activity against Gram-negative clinical
isolates, including KPC- and extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae. In the phase 3, noninferiority TANGO I trial in patients with cUTIs, intravenous meropenem/vaborbactam was noninferior to intravenous piperacillin/
tazobactam for overall success (composite of clinical cure and microbial eradication; FDA primary endpoint) and microbial
eradication (EMA primary endpoint)

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Meropenem
Urinary Tract Infections

Specific Detail Info

Drugs (2018) 78:1259–1270

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment